Amgen Inc. (NASDAQ:AMGN) Shares Purchased by CFO4Life Group LLC

CFO4Life Group LLC raised its position in shares of Amgen Inc. (NASDAQ:AMGN) by 4.0% during the 1st quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 2,169 shares of the medical research company’s stock after buying an additional 84 shares during the quarter. CFO4Life Group LLC’s holdings in Amgen were worth $617,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also recently bought and sold shares of the company. BOK Financial Private Wealth Inc. acquired a new stake in shares of Amgen during the 4th quarter worth approximately $29,000. United Community Bank acquired a new stake in shares of Amgen during the 4th quarter worth approximately $29,000. Horizon Financial Services LLC acquired a new stake in shares of Amgen during the 1st quarter worth approximately $28,000. Planned Solutions Inc. acquired a new stake in shares of Amgen during the 4th quarter worth approximately $30,000. Finally, Delos Wealth Advisors LLC raised its position in shares of Amgen by 2,500.0% during the 4th quarter. Delos Wealth Advisors LLC now owns 104 shares of the medical research company’s stock worth $30,000 after purchasing an additional 100 shares during the period. Institutional investors and hedge funds own 76.50% of the company’s stock.

Amgen Price Performance

Shares of AMGN traded up $8.34 during trading hours on Friday, hitting $333.43. 1,159,264 shares of the company were exchanged, compared to its average volume of 2,708,972. The firm has a fifty day simple moving average of $308.79 and a 200-day simple moving average of $294.36. The company has a market capitalization of $178.86 billion, a PE ratio of 46.88, a PEG ratio of 2.91 and a beta of 0.58. Amgen Inc. has a one year low of $224.34 and a one year high of $333.85. The company has a debt-to-equity ratio of 11.96, a current ratio of 1.42 and a quick ratio of 0.98.

Amgen (NASDAQ:AMGN) last released its earnings results on Thursday, May 2nd. The medical research company reported $3.96 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $3.76 by $0.20. The company had revenue of $7.45 billion during the quarter, compared to analyst estimates of $7.45 billion. Amgen had a return on equity of 156.21% and a net margin of 12.74%. The company’s revenue for the quarter was up 22.0% on a year-over-year basis. During the same quarter in the prior year, the company earned $3.98 earnings per share. As a group, sell-side analysts predict that Amgen Inc. will post 19.47 earnings per share for the current year.

Insider Activity

In other news, SVP Nancy A. Grygiel sold 2,117 shares of the stock in a transaction on Friday, May 3rd. The stock was sold at an average price of $313.09, for a total value of $662,811.53. Following the completion of the sale, the senior vice president now owns 9,883 shares in the company, valued at $3,094,268.47. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Corporate insiders own 0.69% of the company’s stock.

Analyst Upgrades and Downgrades

A number of brokerages have recently weighed in on AMGN. Raymond James began coverage on Amgen in a research report on Thursday, March 28th. They set a “market perform” rating on the stock. UBS Group increased their price objective on Amgen from $284.00 to $307.00 and gave the stock a “neutral” rating in a report on Friday, May 3rd. Barclays raised Amgen from an “underweight” rating to an “equal weight” rating and increased their price objective for the stock from $230.00 to $300.00 in a report on Friday, May 3rd. Argus increased their price objective on Amgen from $300.00 to $340.00 and gave the stock a “buy” rating in a report on Thursday, June 27th. Finally, Truist Financial reissued a “buy” rating and issued a $320.00 price objective on shares of Amgen in a report on Friday, April 12th. Ten investment analysts have rated the stock with a hold rating and twelve have assigned a buy rating to the company. According to MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $307.00.

About Amgen

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.